Midi Health Pricing History, Trajectory, and Whether It's Worth It for Perimenopause Care

What Is Midi Health and Who Is It For?

Midi Health is a women's telehealth company founded in 2021 and headquartered in California. Its entire clinical focus is midlife women, specifically those experiencing perimenopause and menopause symptoms. That narrow focus is its clearest differentiator from general telehealth platforms.

The platform offers video visits with clinicians who have completed menopause-specific training, not just general primary care providers who happen to see menopausal patients as a side service. Clinicians on the platform can prescribe hormone therapy (HT), non-hormonal prescription options for hot flashes such as fezolinetant (Veozah) or low-dose paroxetine (Brisdelle), and adjunct treatments for sleep, mood, and sexual health.

Who Midi Is Designed For

Midi's stated target patient is a woman between roughly 40 and 65 who is experiencing one or more of these: irregular periods, hot flashes, night sweats, brain fog, mood changes, vaginal dryness (genitourinary syndrome of menopause, or GSM), or low libido. The platform does not provide obstetric care, prenatal visits, or fertility treatments such as IVF.

Who It Is Not Right For

If you are trying to conceive, are currently pregnant, or are in the early postpartum period and seeking lactation support, Midi is not the right platform. Women with complex gynecologic conditions such as active endometriosis requiring surgical evaluation, or those who need in-person pelvic exams, will also need to supplement Midi care with an in-person provider.

Midi Health Pricing History: What We Know and What Has Changed

Midi's pricing has not been transparently published in a static, archivable format, which makes reconstructing its full history difficult. Here is what is known from publicly available sources, user reports, and news coverage.

Launch Phase (2021-2022): Low-Cost Entry

When Midi launched in 2021, it positioned itself as an accessible, insurance-forward platform. Early users reported that if Midi accepted their insurance, out-of-pocket costs were similar to a standard specialist copay, typically $20-$50 per visit depending on the plan. Cash-pay patients in this era reported initial consultation fees in the range of $150-$175, with follow-up visits around $75-$100.

At this stage, there was no mandatory annual membership fee layered on top of visit costs. This made Midi comparatively affordable against competitors such as Evernow, which charged subscription fees from launch.

2023: Introduction of Membership Tiers

By 2023, Midi shifted toward a model that includes a membership component. Users in forums including Menopause subreddit threads and the Menopause Society's patient community began reporting that certain services, particularly care coordination, messaging between visits, and priority scheduling, were bundled into a membership tier rather than available a la carte.

Reported annual membership fees in 2023 ranged from $198 to $295 per year depending on the tier, layered on top of, not instead of, visit copays or cash-pay consultation fees.

2024-2025: Tiered Model and Price Increases

The most recent publicly reported pricing as of early 2025 places Midi's cash-pay initial consultation at approximately $250-$295. Follow-up visits for cash-pay patients are reported at $150-$175. For patients using insurance, visit costs depend entirely on the individual plan's specialist copay or deductible status.

A membership fee for ongoing care access, messaging, and care coordination ranges from approximately $195 to $395 per year depending on the tier selected. Midi has not published a clear, dated pricing page with historical archives, so these figures are drawn from user-reported data and third-party coverage.

The pricing trajectory is clearly upward. From launch to 2025, cash-pay initial consultation costs have increased by roughly 40-70% in absolute terms. This mirrors a broader trend in women's telehealth: platforms raise prices as they establish clinical credibility and reduce their reliance on venture-capital subsidies for patient acquisition.

How Midi Compares to Other Menopause Telehealth Platforms

| Platform | Initial Visit (Cash) | Membership Fee | Insurance Accepted | |---|---|---|---| | Midi Health | ~$250-$295 | ~$195-$395/yr | Yes, many plans | | Evernow | ~$99 (subscription-only) | Required monthly or annual sub | No | | Alloy Health | ~$93 initial assessment | Monthly sub for ongoing care | Limited | | Gennev (now part of Unified Women's Healthcare) | Varied | Legacy model changed post-acquisition | Limited | | In-person OB-GYN or menopause specialist | $200-$500+ out-of-pocket if not in-network | None | Yes, if in-network |

Is Midi Health Legit? An Evidence-Based Assessment

The short answer: yes, Midi is a legitimate licensed telehealth company staffed by real clinicians. The longer answer requires looking at its licensing, clinical standards, prescribing practices, and complaint history.

Clinician Licensing and Credentials

Midi employs NPs (nurse practitioners), PAs (physician assistants), and MDs/DOs. Each clinician is independently licensed in the states where they practice. Midi has stated that its clinicians complete training aligned with The Menopause Society (NAMS) clinical guidance, though the platform does not specify whether individual clinicians hold the NAMS Certified Menopause Practitioner (NCMP) credential.

This is a meaningful distinction. The NCMP credential requires a formal examination and continuing education in menopause medicine. A clinician who has completed Midi's internal training is not automatically equivalent to an NCMP. If this credential matters to you, ask your Midi clinician directly whether they hold it.

State Telehealth Licensing

Telehealth prescribing requires that the clinician be licensed in the patient's state. Midi operates across more than 30 U.S. States as of 2025, but availability varies. Women in rural states or states with more restrictive telehealth prescribing laws may find access limited, particularly for controlled substances such as low-dose testosterone, which some menopause specialists prescribe off-label for HSDD (hypoactive sexual desire disorder) in postmenopausal women.

Prescribing Practices: Are They Evidence-Based?

Midi's clinical protocols are broadly aligned with The Menopause Society's 2023 position statement on hormone therapy, which states that HT is the most effective treatment for vasomotor symptoms and is appropriate for most healthy women under 60 or within 10 years of menopause onset. The Menopause Society's 2023 statement notes that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms."

Clinicians at Midi can prescribe FDA-approved hormone therapy formulations including estradiol patches, gels, and sprays, oral progesterone (Prometrium), and vaginal estrogen products such as Estrace cream or Vagifem tablets. They can also prescribe non-hormonal FDA-approved options: fezolinetant (Veozah), approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms, and paroxetine 7.5 mg (Brisdelle), the only SSRI with an FDA indication specifically for menopausal hot flashes.

BBB Rating and Complaint History

Midi Health is not accredited by the Better Business Bureau. As of mid-2025, the BBB profile for Midi Health shows a pattern of complaints in several recurring categories: billing disputes, difficulty canceling membership fees, delayed prescription processing, and clinician responsiveness between visits.

These are not rare complaints for telehealth platforms, but the billing and cancellation issues deserve specific attention. Several users have reported that the annual membership fee renewed automatically without clear advance notice, and that getting a refund required multiple contacts with customer support. This is a legitimate consumer concern, distinct from clinical quality.

No FDA warning letters, state medical board enforcement actions, or LegitScript suspension notices specific to Midi Health were identifiable in publicly available records as of the publication date of this article. That is a meaningful absence of red flags at the regulatory level.

Midi Health Complaints: Patterns Worth Knowing

Across BBB filings, Reddit threads (r/Menopause, r/Perimenopause), and third-party review aggregators, the most common complaints about Midi fall into four categories.

Billing and Auto-Renewal

The most frequent complaint involves the membership fee auto-renewing without sufficient notice. Some users report seeing the charge before receiving an email reminder. If you sign up for Midi, set a personal calendar reminder 30 days before your annual renewal date and confirm the cancellation policy in writing at signup.

Wait Times for Initial Appointments

Some users report waits of two to three weeks for an initial consultation, particularly in high-demand states such as California, Texas, and New York. This is a real operational limitation. If you are in acute distress from severe symptoms, a two-to-three-week wait may not be acceptable. In that case, consider calling your OB-GYN for a bridge consultation while you wait.

Clinician Variability

Because Midi uses multiple clinicians, some users report inconsistency between their first and second visits if they see different providers. The platform does allow you to request a specific clinician for follow-ups, but this is not always possible with scheduling constraints.

Prescription Delays

A subset of complaints involves delays in getting prescriptions sent to the pharmacy, particularly for specialty formulations such as compounded bioidentical hormone preparations. Midi's position on compounded hormones is worth clarifying: the platform generally prefers FDA-approved commercial formulations, consistent with ACOG's guidance on compounded hormone therapy, which states that compounded preparations "are not FDA-approved" and "there is little evidence that they are safer or more effective than conventional menopausal hormone therapy."

What Midi Prescribes: The Drug and Hormone Menu

Understanding what Midi can and cannot prescribe helps you evaluate whether the platform fits your clinical needs.

FDA-Approved Hormone Therapy Options

Midi clinicians can prescribe the full range of FDA-approved systemic hormone therapy. For women with a uterus, any systemic estrogen must be paired with progestogen to protect the endometrium. The Menopause Society recommends micronized progesterone (Prometrium) as the preferred progestogen due to a more favorable risk profile compared with synthetic progestins, based in part on data from the E3N cohort study, which found lower breast cancer risk with micronized progesterone versus synthetic progestins in French postmenopausal women.

Local Vaginal Estrogen

For GSM (vaginal dryness, dyspareunia, recurrent UTIs), Midi can prescribe low-dose vaginal estrogen in cream, tablet, or ring form. ACOG confirms that low-dose vaginal estrogen has minimal systemic absorption and is appropriate even for women with a history of breast cancer in most cases, though oncologist coordination is advised. This is a high-value service that many general telehealth platforms do not offer confidently.

Non-Hormonal Prescription Options

Beyond hormone therapy, Midi can prescribe:

• Fezolinetant (Veozah): a neurokinin B receptor antagonist, FDA-approved for vasomotor symptoms, at 45 mg once daily
• Paroxetine 7.5 mg (Brisdelle): FDA-approved SSRI for hot flashes
• Gabapentin: used off-label for night sweats and sleep disruption
• Low-dose SSRIs/SNRIs (venlafaxine, escitalopram) for mood and vasomotor symptoms

Pregnancy, Lactation, and Contraception Considerations

Midi Health's platform is not designed for pregnancy or postpartum care, but several of the medications it prescribes require explicit pregnancy and contraception guidance.

Systemic Hormone Therapy

Systemic estrogen and progestogen preparations are contraindicated in pregnancy. Women in perimenopause who have not confirmed menopause (defined as 12 consecutive months without a period) can still ovulate and conceive. If you are perimenopausal and sexually active with a male partner, you need reliable contraception while on systemic HT. Low-dose combined oral contraceptives are sometimes used in perimenopausal women both for contraception and symptom management; Midi can discuss this option.

Estrogen and progesterone do transfer into breast milk. Women who are breastfeeding should discuss the risk-benefit profile with their clinician before starting systemic HT, though postmenopausal women on HT are, by definition, not breastfeeding.

Fezolinetant (Veozah)

Fezolinetant's FDA label states that animal reproductive studies showed adverse developmental effects at doses higher than the clinical dose. There are no adequate human pregnancy data. The drug should not be used during pregnancy. Because women in perimenopause may still be fertile, clinicians should confirm contraception status before prescribing.

Paroxetine (Brisdelle)

Paroxetine carries FDA Pregnancy Category D, meaning there is positive evidence of human fetal risk. The 2006 ACOG Practice Bulletin on psychiatric medications in pregnancy warned specifically about paroxetine exposure in the first trimester and a small but measurable increase in cardiac septal defects. Paroxetine should not be started in a woman who may be pregnant, and perimenopausal women prescribed it need a confirmed negative pregnancy test and a reliable contraceptive plan.

Paroxetine transfers into breast milk in small amounts. The American Academy of Pediatrics has listed paroxetine as a drug whose effect on nursing infants is unknown but may be of concern. Brisdelle is not indicated for postpartum women who are nursing.

Life-Stage Guide to Using Midi Health

Perimenopause (Typically Ages 40-52)

This is Midi's primary clinical sweet spot. Perimenopause, the transition phase before menopause, is marked by erratic estrogen fluctuations that cause irregular periods, mood instability, sleep disruption, and early vasomotor symptoms. Up to 80% of women experience vasomotor symptoms during this transition, and many go years without an accurate diagnosis or treatment. Midi explicitly addresses this underserved gap.

Women in this stage who still have a uterus need both estrogen and progestogen if starting systemic HT. They also need contraception if they are sexually active and not confirmed menopausal.

Menopause and Early Post-Menopause (Typically Ages 50-60)

For women within 10 years of their final menstrual period, the evidence for HT benefit is clearest. The Women's Health Initiative Memory Study and subsequent re-analyses have shown that HT started in this window does not carry the elevated dementia risk initially feared from older WHI data. Midi's clinical model fits well here, with ongoing prescription management and symptom tracking via video follow-up.

Late Post-Menopause (Ages 60+)

Women more than 10 years past menopause or over age 60 starting HT for the first time face a different benefit-risk calculation. The Menopause Society notes that in this group, the risk of coronary heart disease and stroke is higher and the evidence base is less favorable for initiating HT. Midi can still serve women in this group, particularly for local vaginal estrogen for GSM, which carries minimal systemic risk. Starting or continuing systemic HT at this stage requires a more individualized conversation about cardiovascular risk.

Evidence Gaps: What We Do Not Know About Telehealth Menopause Care

Women have been historically underrepresented in menopause clinical trials, and telehealth-specific menopause research is even thinner. There are no published randomized controlled trials comparing outcomes (symptom control, HT adherence, quality of life) between women managed via a telehealth-only menopause platform versus in-person menopause specialists. The data supporting HT itself is solid, but the delivery-model comparison is extrapolated from general telehealth effectiveness data, not studied directly in menopause populations.

This matters because Midi's model depends on video visits without physical examination. Conditions that might modify HT candidacy, such as an undiagnosed uterine polyp contributing to irregular bleeding, cannot be detected through a video visit. A clinician at Midi should and typically does refer you for in-person pelvic ultrasound or endometrial biopsy when clinically indicated, but the adequacy and consistency of that referral pattern across Midi's clinician pool is not publicly audited or published.

Should You Use Midi Health? An Honest Verdict by Clinical Situation

Midi is a reasonable choice if:

• You have insurance that covers Midi and your out-of-pocket cost is similar to an in-person specialist copay
• You have typical perimenopausal or menopausal symptoms (hot flashes, night sweats, sleep disruption, GSM) without complex comorbidities
• You live in a state without easy access to an in-person NAMS-certified menopause specialist
• You are comfortable with video visits and digital prescription management

Midi is not the right fit if:

• You are pregnant, trying to conceive, or need postpartum support
• You have complex gynecologic history (prior endometrial cancer, untreated fibroids causing heavy bleeding, recent abnormal Pap) requiring in-person evaluation
• You want a clinician who holds the formal NAMS Certified Menopause Practitioner credential and can confirm it
• The membership fee plus visit costs add up to more than an in-network in-person visit, which is possible depending on your insurance